argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$981.33+3.75 (+0.38%)
Close on Nov 12, 2026Market cap –P/E 50.1Yield –
argenx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $19.57, up 53.1% from the year before. The highest annual figure on record is $19.57 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.57 | +53.1% |
| FY2024 | Dec 31, 2024 | $12.78 | – |
| FY2023 | Dec 31, 2023 | -$5.16 | – |
| FY2022 | Dec 31, 2022 | -$13.05 | – |
| FY2021 | Dec 31, 2021 | -$7.99 | – |
| FY2020 | Dec 31, 2020 | -$13.40 | – |
| FY2019 | Dec 31, 2019 | -$4.69 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?